Arzerra(ofatumumab)
Kesimpta (ofatumumab) is an antibody pharmaceutical. Ofatumumab was first approved as Arzerra on 2009-10-26. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia and relapsing-remitting multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Kesimpta (discontinued: Kesimpta)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| lymphoid leukemia | — | D007945 | C91 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ofatumumab, Arzerra, Novartis Pharmaceuticals Corporation | |||
| 2123-01-19 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FA: Cd20 (clusters of differentiation 20) inhibitors
— L01FA02: Ofatumumab
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA52: Ofatumumab
HCPCS
Code | Description |
|---|---|
| J9302 | Injection, ofatumumab, 10 mg |
Clinical
Clinical Trials
176 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 4 | 9 | 9 | 38 | 60 |
| Leukemia | D007938 | — | C95 | 9 | 41 | 10 | 1 | 1 | 59 |
| Lymphoid leukemia | D007945 | — | C91 | 9 | 41 | 10 | 1 | 1 | 59 |
| Sclerosis | D012598 | — | — | — | 4 | 9 | 8 | 35 | 56 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 9 | 37 | 10 | 1 | 1 | 55 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 3 | 7 | 6 | 13 | 29 |
| Covid-19 | D000086382 | — | — | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 13 | 40 | 6 | — | — | 53 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 12 | 1 | — | — | 18 |
| B-cell lymphoma | D016393 | — | — | 3 | 11 | 1 | — | — | 15 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 9 | 1 | — | — | 11 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 8 | 1 | — | — | 9 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 2 | 2 | — | — | 5 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | 2 | 2 | — | — | 5 |
| Pemphigus | D010392 | EFO_1000749 | L10 | — | — | 2 | — | 1 | 3 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | — | 1 | — | 1 | 2 |
| Prolymphocytic leukemia t-cell | D015461 | — | C91.6 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | — | 7 | — | — | — | 7 |
| Recurrence | D012008 | — | — | 2 | 3 | — | — | — | 5 |
| Mantle-cell lymphoma | D020522 | — | — | 2 | 4 | — | — | — | 5 |
| Syndrome | D013577 | — | — | — | 3 | — | — | 1 | 4 |
| Burkitt lymphoma | D002051 | — | C83.7 | — | 3 | — | — | — | 3 |
| Hodgkin disease | D006689 | — | C81 | 1 | 2 | — | — | — | 3 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | 2 | — | — | — | 3 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 2 | — | — | 1 | 3 |
| Nephrosis | D009401 | — | — | — | 2 | — | — | 1 | 3 |
| Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | — | 2 | — | — | — | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| T-cell lymphoma | D016399 | — | — | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Mycosis fungoides | D009182 | — | C84.0 | 1 | — | — | — | — | 1 |
| T-cell lymphoma cutaneous | D016410 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 2 | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Demyelinating diseases | D003711 | — | — | — | — | — | — | 1 | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
| Optical coherence tomography | D041623 | — | — | — | — | — | — | 1 | 1 |
| Retinal degeneration | D012162 | HP_0001105 | — | — | — | — | — | 1 | 1 |
| Visual acuity | D014792 | — | — | — | — | — | — | 1 | 1 |
| Atrophy | D001284 | — | — | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ofatumumab |
| INN | ofatumumab |
| Description | Immunoglobulin G1, anti-(human CD20 (antigen))(human monoclonal HuMax-CD20 heavy chain), disulfide with human monoclonal HuMax-CD20 kappa-chain, dimer |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >3GIZ:H|Fab fragment of anti-CD20 antibody Ofatumumab, heavy chain
EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLY
LQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
>3GIZ:L|Fab fragment of anti-CD20 antibody Ofatumumab, light chain
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEP
EDFAVYYCQQRSNWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR |
Identifiers
| PDB | 3GIZ, 6Y92 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201836 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06650 |
| UNII ID | M95KG522R0 (ChemIDplus, GSRS) |
Target
Agency Approved
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
MS4A1
Gene synonyms
CD20
NCBI Gene ID
Protein name
B-lymphocyte antigen CD20
Protein synonyms
B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, CD20, CD20 antigen, CD20 receptor, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1
Uniprot ID
Mouse ortholog
Ms4a1 (12482)
B-lymphocyte antigen CD20 (P19437)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Kesimpta – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,505 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arzerra
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,372 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use